Randomized Phase II 2x2 Factorial Trial of the addition of carboplatin and/pr bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense ac in hormone receptor-poor/HER2-negative respectable breast cancer
ID Number 58-0056 (40603)Principal Investigator(s)
Elisa R. Port
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to see if adding other drugs to standard neoadjuvant chemotherapy (treatment prior to surgery) can help shrink triple-negative breast cancer faster, and lower the risk of the cancer coming back in other parts of the body.
You may qualify to take part in this research study because you have been diagnosed with “triple negative” breast cancer. “Triple negative” breast cancer is an invasive kind of breast cancer meaning that is can spread. This cancer does not respond to the female hormones called estrogen and progesterone, and does not overexpress(over-producing) the HER2 protein which means that it would not be expected to respond to the drug trastuzumab, also called Herceptin. Because of the size and extent of your cancer, your health care team believes that it would be better to try to shrink the cancer before surgery. This may make it easier to remove and will let your doctors see how well it responds to treatment.
Recruiting Patients: Yes